The Effect of Triflusal on Peripheral Microcirculation Dysfunction

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Aspirin; Salicylates; Triflusal

Criteria

Inclusion Criteria:

• Between 40 and 70 years of age

• Diagnosed vasospastic syndrome with nailfold capillaroscopy (Fingertip is subjected to carbon dioxide at -15°C for 60 seconds. People found to have a blood-flow standstill of at least 12s in one or more capillaries were defined as having vasospasticity)

• More than seven points in 10-question interview provided by Nagashima et al.

• Written informed consent

Exclusion Criteria:

• Prior documented diabetes

• Overt peripheral artery disease

• Pregnant or nursing

• bleeding tendency

• Any contraindication of antiplatelet agent

• Thrombocytopenia (platelet < 100,000mm3)

• Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl)

• Patients who can not stop to take aspirin